Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE ...

Meet Mariano Barbacid, the Spanish scientist behind a breakthrough that erased pancreatic cancer in mice and reignited hope ...

Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. The U.S. tech giant will provide its suite of artificial-intelligence-powered radiology ...

Long-term alliances in pharma enable strategic resource planning and infrastructure development, supporting diverse therapeutic pipelines and ensuring operational reliability. Integrated research, ...

Former USMNT goalkeeper and soccer analyst Kasey Keller detailed his previously undisclosed cancer battle for the first time ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...

Also, don’t miss ✨LIVE MUSIC TONIGHT✨ on the Merrick Patch calendar ...

Miguel Angel Perez, of the farmers organisation COAG in Andalusia's Cadiz province, told Spanish television TVE on Saturday: ...